Linrodostat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Linrodostat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Linrodostat can convert its Small molecule drug profile and IDO1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Linrodostat (query alias: Linrodostat) |
|---|---|
| Modality / target | Small molecule drug; IDO1; IDO1 inhibitors |
| Highest global status | Phase 2 |
| Originator | Bristol Myers Squibb Co. |
| Active developers | Bristol Myers Squibb Co. |
The MCP disease footprint includes Carcinosarcoma, Recurrent Endometrial Cancer, Uterine Carcinosarcoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04106414 | Phase 2 | Active, not recruiting | 24 | Primary endpoint not disclosed in English source |
| NCT04047706 | Phase 1 | Active, not recruiting | 18 | Primary endpoint not disclosed in English source |
| NCT04007588 | Phase 2 | Withdrawn | 0 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Phase 1/2; n=229; evaluation: Not stated in English source. Reported fields: Hemoglobin level = 0 Pts ; Hemoglobin level = 0 Pts
Phase I/II Trial of BMS-986205 and Nivolumab as First or Second Line Therapy in Hepatocellular Carcinoma
Phase 1/2; n=8; evaluation: Not stated in English source. Reported fields: Diarrhea = 2 Pts
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
Phase 2; n=142; evaluation: Not stated in English source. Reported fields: Number of Participants With Adverse Events (AEs) = 15 Pts ; Number of Participants With Adverse Events (AEs) = 26 Pts
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Linrodostat addresses Carcinosarcoma, Recurrent Endometrial Cancer, Uterine Carcinosarcoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 8 matched transaction record(s) under the scope “target-level comparable: IDO1.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IDO1 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-05-23 | Hornet emerges from stealth with a strategic partnership with Kyowa Kirin | Phase 1 | Financial terms not disclosed |
| 2019-04-02 | BriaCell plans to assess the impact of combining Bria-IMT with Incyte's INCMGA-0012 and epacadostat in treating advanced breast cancer. | Not disclosed | Financial terms not disclosed |
| 2018-11-02 | Kyowa Hakko Kirin Announces a Phase 1 Clinical Study of its IDO inhibitor in solid tumor, under a collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combinations treatments of diacylglycerol kinase (DGK) alpha inhibitors and other therapies”. The milestone feed surfaced a patent-application signal described as “Hypoxia inducible factor-2(ALPHA) inhibitors for the treatment of bladder cancer”. The milestone feed surfaced a patent-application signal described as “Application of Linodostat in preparation of medicine for treating bladder cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
